Skip to main content
Micro-Tech (Nanjing) Co.,Ltd logo

Micro-Tech (Nanjing) Co.,Ltd — Investor Relations & Filings

Ticker · 688029 ISIN · CNE100003MG1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 662 across all filing types
Latest filing 2021-11-29 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688029

About Micro-Tech (Nanjing) Co.,Ltd

https://www.micro-tech.com.cn/

Micro-Tech (Nanjing) Co., Ltd. specializes in the research, development, and manufacturing of minimally invasive medical devices. The company focuses on providing advanced solutions for gastroenterology, respiratory medicine, and orthopedics. Its product portfolio includes a wide range of endoscopic diagnostic and therapeutic tools such as biopsy forceps, disposable hemoclips, biliary and esophageal stents, and specialized instruments for Endoscopic Mucosal Resection (EMR) and Endoscopic Submucosal Dissection (ESD). Micro-Tech emphasizes innovation and quality, maintaining international certifications to serve a global healthcare market. By integrating precision engineering with clinical needs, the company aims to improve patient outcomes and procedural efficiency for medical professionals worldwide.

Recent filings

Filing Released Lang Actions
南微医学科技股份有限公司第三届监事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the fourth meeting of the third Supervisory Board of Nanwei Medical Technology Co., Ltd. It details the approval of adjustments to the 2020 restricted stock incentive plan grant price and the granting of reserved restricted stock to incentive recipients. The document includes voting results and references related announcements published on the Shanghai Stock Exchange website. It is not a full report like an annual or interim report, nor is it a financial statement or earnings release. It is also not a regulatory filing or certification. The content focuses on supervisory board meeting resolutions regarding stock incentive plans, which fits best under Board/Management Information (MANG) as it relates to governance and management decisions about stock incentives. The document length is short (1516 characters), and it is a meeting resolution announcement rather than a full report or presentation.
2021-11-29 Chinese
北京金诚同达律师事务所关于南微医学科技股份有限公司2020年限制性股票激励计划授予价格调整及预留授予相关事项之法律意见书
Regulatory Filings
2021-11-29 Chinese
南微医学科技股份有限公司独立董事关于第三届董事会第五次会议相关事项的独立意见
Regulatory Filings
2021-11-29 Chinese
南微医学科技股份有限公司2021年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2021 年第三季度报告' which translates to '2021 Third Quarter Report'. It contains detailed financial data including income statements, balance sheets, cash flow statements, and notes for the third quarter of 2021. The document explicitly states it is a quarterly report and includes unaudited financial statements for the period ending September 30, 2021. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is a full interim/quarterly financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2021
2021-10-27 Chinese
南微医学科技股份有限公司第三届监事会第三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolution passed at the third meeting of the third Supervisory Board of the company. It includes the approval of the company's 2021 third quarter report and a donation proposal. The document states that the detailed 2021 third quarter report is disclosed on the Shanghai Stock Exchange website, indicating this document itself is not the full quarterly report but an announcement of the meeting's resolutions and approval of that report. The document length is short (768 characters), and it does not contain actual financial statements or substantive financial data, only a summary of the meeting and voting results. Therefore, it is not an Interim/Quarterly Report (IR) but rather a Regulatory Filing (RNS) as a general announcement of meeting resolutions and report approval.
2021-10-27 Chinese
南微医学科技股份有限公司关于达成诉讼和解及专利许可的公告
Legal Proceedings Report Classification · 95% confidence The document is a public announcement by 南微医学科技股份有限公司 regarding the settlement of litigation and patent licensing agreements with Boston Scientific. It details the background of multiple patent infringement lawsuits, the terms of the settlement and licensing agreements, and the financial impact on the company. The document is an announcement of legal proceedings resolution and related patent licensing, not a full audit report or annual report. It does not contain financial statements or detailed financial analysis but focuses on legal and licensing matters. Therefore, it fits best under the category of Legal Proceedings Report (LTR). The document length is about 4013 characters, which is sufficient for a detailed announcement but not a full financial report. Hence, the classification is LTR with high confidence.
2021-10-20 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.